AstraZeneca withdraws COVID-19 vaccine globally, cites ‘commercial reason’

The vaccine maker indicated that the global withdrawal was started for commercial reasons

The vaccine maker indicated that the global withdrawal was started for commercial reasons
The vaccine maker indicated that the global withdrawal was started for commercial reasons

Know why AstraZeneca recalled COVID-19 vaccine

AstraZeneca has announced that it will withdraw its COVID-19 vaccine globally. This comes days after it was revealed that the British pharmaceutical giant had acknowledged that the vaccine may have rare side effects.

According to AstraZeneca, the vaccination has been replaced by revised shots that address novel variations.

Due to a “surplus of available updated vaccines” for COVID-19, the vaccine maker indicated that the global withdrawal was started for commercial reasons, according to The Telegraph.

AstraZeneca is being sued for a hundred million pounds in the UK on the grounds that the COVID-19 vaccine resulted in multiple fatalities and injuries.

Other nations that have been using will also make withdrawals.

In February, AstraZeneca acknowledged that Covishield may “in very rare cases, cause TTS or Thrombosis with Thrombocytopenia Syndrome” in a court declaration.

In the European Union, the business voluntarily withdrew its “marketing authorization,” stating that the vaccine was no longer in production and could not be administered.

“According to independent estimates, over 6.5 million lives were saved in the first year of use alone, and over three billion doses were supplied globally. Our efforts have been recognized by governments around the world and are widely regarded as being a critical component of ending the global pandemic. As multiple, variant COVID-19 vaccines have since been developed, there is a surplus of available updated vaccines. We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the COVID-19 pandemic,” AstraZeneca said in a statement.

TTS has been connected to at least 81 deaths in the UK and causes blood clots and low blood platelet counts in people.

However, AstraZeneca has denied any connection between the court case and the decision to discontinue Covishield.

For all the latest updates, download PGurus App.

LEAVE A REPLY

Please enter your comment!
Please enter your name here